Intellectual Property DisputeThis transaction reduces perceived BD optionality and heightens dependence on success in its IP dispute.
Partnership ConcernsCVAC's inability to secure a BioPharma partner for these programs is a disappointment against investor expectations.
Vaccine EfficacyImmunogenicity results were mixed, with geometric mean titers against influenza A strains exceeding that of licensed comparator vaccines, but inferior against influenza B strains across all age groups and tested dose levels.